A novel protocol allowing oral delivery of a protein complement inhibitor that subsequently targets to inflamed colon mucosa and ameliorates murine colitis

While there is evidence of a pathogenic role for complement in inflammatory bowel disease, there is also evidence for a protective role that relates to host defence and protection from endotoxaemia. There is thus concern regarding the use of systemic complement inhibition as a therapeutic strategy....

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Exp Immunol
Prif Awduron: Elvington, M, Blichmann, P, Qiao, F, Scheiber, M, Wadsworth, C, Luzinov, I, Lucero, J, Vertegel, A, Tomlinson, S
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Blackwell Science Inc 2014
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226601/
https://ncbi.nlm.nih.gov/pubmed/24730624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.12350
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg